Daniel Sumarriva/LinkedIn
May 21, 2025, 07:09
Daniel Sumarriva: I’m Starting a New Position as Executive Medical Director at SAGA Diagnostics
Daniel Sumarriva, Executive Medical Director at SAGA Diagnostics, posted on LinkedIn:
“I’m happy to share that I’m starting a new position as Executive Medical Director at SAGA Diagnostics! leading medical and strategic scientific initiatives for our novel minimal residual disease (MRD) assay Pathlight.
Throughout my career in clinical research, medical affairs, and precision oncology, I’ve seen firsthand the transformative potential of blood-based biomarkers and circulating tumor DNA (ctDNA) technologies to revolutionize patient care. Joining SAGA represents not only a meaningful career milestone but also a deeply personal commitment to advancing innovations that truly address unmet clinical needs.
My shared mission to improving outcomes in early-stage cancer aligns perfectly with the groundbreaking work at SAGA. Pathlight MRD was thoughtfully developed with cancer biology at its core, directly addressing many critical gaps we face today in MRD testing.
I’m honored to collaborate with a passionate team of dynamic professionals and entrepreneurs, all driven by the vision of advancing precision medicine, and as I embark on this exciting journey, I’m grateful to everyone who’s supported and inspired me along the way.
Let the Saga begin!”
More posts featuring Daniel Sumarriva.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 21, 2025, 06:44
May 21, 2025, 06:37
May 21, 2025, 06:28
May 21, 2025, 06:19
May 21, 2025, 06:06
May 21, 2025, 04:12
May 21, 2025, 03:33